Evidence map›Paper›PMID 38409703›Full record

ReviewCurrent molecular medicine2025

Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers.

Abhinav Verma, Mittal Rishabh, Navaneethakannan Mathiyazhagan, Sonu Singh Ahirwar, Sukhes Mukherjee, Ashwin Kotnis

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Abhinav VermaDepartment of Biochemistry, All India Institute of Medical Sciences Bhopal, Saket Nagar, Bhopal, Madhya Pradesh, India.
Mittal RishabhDepartment of Biochemistry, All India Institute of Medical Sciences Bhopal, Saket Nagar, Bhopal, Madhya Pradesh, India.
Navaneethakannan MathiyazhaganDepartment of Biochemistry, All India Institute of Medical Sciences Bhopal, Saket Nagar, Bhopal, Madhya Pradesh, India.ORCID 0000-0001-6551-9928
Sonu Singh AhirwarDepartment of Biochemistry, All India Institute of Medical Sciences Bhopal, Saket Nagar, Bhopal, Madhya Pradesh, India.ORCID 0000-0003-2914-3665
Sukhes MukherjeeDepartment of Biochemistry, All India Institute of Medical Sciences Bhopal, Saket Nagar, Bhopal, Madhya Pradesh, India.
Ashwin KotnisDepartment of Biochemistry, All India Institute of Medical Sciences Bhopal, Saket Nagar, Bhopal, Madhya Pradesh, India.ORCID 0000-0002-0995-6266
All India Institute of Medical Sciences Bhopal · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease is a globally prevalent disorder that can rapidly progress if not detected early. Currently, no accepted markers exist for early diagnosis and prognosis of NAFLD. This review describes derangement in major metabolic pathways of lipid, carbohydrate, and amino acids in NAFLD. It suggests that measuring levels of thrombospondin, TyG index, asymmetric dimethylarginine, LAL-A, GLP-1, FGF-21, and GSG index are potential markers for early diagnosis of NAFLD. A single marker may not indicate early NAFLD, and further large-scale studies on correlating levels of Thrombospondin-2, triglyceride-glucose index, and FGF-21 with NAFLD are warranted.

Indexed as

BiomarkersNon-alcoholic Fatty Liver DiseaseEarly DiagnosisFibroblast Growth FactorsHumansLipid MetabolismPrognosisBiomarkersFibroblast Growth Factorscytokeratin.dyslipidemiainsulin resistanceMAFLDmetabolic derangementNAFLDNASHRNA splicingsteatosis TyG indexthrombospondin

Identifiers

PMID38409703
OpenAlexW4392195321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.